Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.
uniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
uniQure: Its Promising Research Pipeline
uniQure (QURE) is advancing a pipeline of gene therapies that are developed internally and externally. It has a collaboration with Bristol-Myers Squibb (BMY).
BioMarin Pharmaceutical and Its Promising Research Pipeline
Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.